By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
Improve efficiency, reduce late-stage failures, and align with regulatory standards by assessing the proarrhythmic liability of your compounds early. The potency data derived from high-fidelity platforms such as automated patch-clamp and the gold standard manual patch-clamp technique, is suitable for use in in silico action potential models. Our full cardiac ion channel panel includes: hERG (including a robust, dynamic hERG assay), KVLQT1/mink, hKV4.3/KChIP, hCaV1.2, hNaV1.5 (peak and late), hKIR2.1. Screening services against hHCN4 and hKV1.5, which play important roles in controlling human heart rate and atrial repolarisation, respectively, are also provided.
Learn more about our cardiac ion channel panel.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.